Blum Robert I 4
Research Summary
AI-generated summary
Cytokinetics (CYTK) CEO Robert I. Blum Sells 7,500 Shares
What Happened Robert I. Blum, President & CEO and a director of Cytokinetics (CYTK), reported an open-market sale of 7,500 shares on April 29, 2026. The shares were sold at $59.62 each for a total transaction value of approximately $447,150. This was a sale (code S) — not a purchase or option exercise.
Key Details
- Transaction date and price: April 29, 2026 — 7,500 shares at $59.62 per share.
- Total proceeds: ~ $447,150.
- Shares owned after transaction: not specified in the provided filing.
- Footnotes: F1 and F2 indicate shares held by The Bridget Blum 2003 Irrevocable Trust and The Brittany Blum 2003 Irrevocable Trust.
- Timeliness: Filing date and transaction date are both April 29, 2026 — appears timely (no late filing flagged).
Context Sales by executives are common and can reflect routine diversification or liquidity needs; they do not by themselves indicate the insider's view of the company’s prospects. This report documents a straightforward share sale; there’s no indication in the filing of option exercises, 10b5-1 plans, or gifts related to this transaction.